ABBOTT LABORATORIESABT
ABBOTT LABORATORIES Financial Overview 2020–2024
Abbott Laboratories has aggressively pivoted from its pandemic-era defensive posture to a growth-focused medical technology strategy, best illustrated by the 18.1% surge in Diabetes Care sales to $6.4 billion in FY2024. The company is successfully offsetting the secular decline in COVID-19 testing revenues by accelerating its Medical Devices segment, which now serves as the primary engine for organic value creation.
Financial performance has strengthened considerably over the long term, with EPS expanding from $2.50 in FY2020 to $7.64 by the close of FY2024. This upward trajectory is supported by a 12.8% revenue increase in Medical Devices during the first nine months of FY2025, driven by robust demand for electrophysiology and structural heart products. Despite a 5.0% contraction in the Diagnostics unit over the same period, management maintained strict operational discipline, pushing gross margins to 52.7% in the first half of FY2025. Capital allocation remains aggressive; the company announced a $7 billion share repurchase program in October 2024 and agreed to acquire Exact Sciences for $105.00 per share in November 2025, deploying a balance sheet that held $7.0 billion in cash mid-year.
Recent Developments (Q2 and Q3 2025)
Abbott generated $32.9 billion in total net sales during the first nine months of 2025, supported by commercial execution on new approvals like the Volt PFA and Tendyne TMVR systems. While the broader portfolio grew, the Diagnostics segment faced specific pressure from challenging market conditions in China, exacerbating the post-pandemic revenue contraction. Management continued to prioritize innovation, increasing R&D expenses by 5.4% to $2.2 billion, which contributed to flat Q3 2025 net earnings of $1.64 billion despite a year-to-date profit increase to $4.75 billion.
The bull case relies on sustained double-digit organic growth in structural heart and diabetes platforms to drive long-term margin expansion. Conversely, bears remain wary of unresolved infant formula litigation and significant tax disputes with the IRS that could impact future cash flows. Trading at 16.3x earnings as of October 2025, the stock reflects a market weighing robust pipeline execution against lingering legal uncertainties.
What to watch: Regulatory and shareholder approvals for the Exact Sciences merger; resolution of ongoing IRS tax deficiency notices.
Rev
$41.95B
FY2024
NI
$13.40B
FY2024
EPS
$7.67
FY2024
OCF
$8.56B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
ABBOTT LABORATORIES 8-K Report, Financial Results (Jan 22, 2026)
Abbott Laboratories (ABT) has filed an 8-K report on January 21, 2026, to announce its fourth quarter and full-year 2025 financial results. The report highlights that the company's earnings release, furnished as an exhibit, will present both GAAP and non-GAAP financial measures. Investors should pay close attention to these non-GAAP figures as Abbott's management utilizes them to provide a clearer view of ongoing operational performance, excluding items such as acquisition-related expenses, restructuring costs, legal reserves, and intangible amortization. The company emphasizes that these non-GAAP measures are intended to offer investors greater visibility into the underlying business performance by adjusting for factors that management considers unusual or unpredictable. While these adjustments aim to facilitate better evaluation of operational trends, investors are advised to consider these non-GAAP measures alongside, and not as a substitute for, the GAAP financial measures. The filing also includes the press release and an interactive data file for enhanced analysis.
ABBOTT LABORATORIES 8-K Report, Executive Changes (Dec 12, 2025)
Abbott Laboratories (ABT) filed an 8-K on December 12, 2025, primarily announcing a change in its Board of Directors composition and size. The company appointed Nita Ahuja, M.D. to its Board, effective December 12, 2025. This appointment increases the total number of directors from twelve to thirteen. The amendment to the company's bylaws formalizes this increase, reflecting a strategic expansion of its governance structure. The filing also notes the amended and restated By-Laws of Abbott Laboratories, effective December 12, 2025, as an exhibit, indicating these governance changes are now officially documented.
ABBOTT LABORATORIES 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Nov 21, 2025)
Abbott Laboratories (ABT) has filed an 8-K to announce a temporary trading suspension, commonly known as a "blackout period," affecting its employee benefit plans. This suspension is due to significant administrative changes within the Abbott Laboratories Stock Retirement Plan (U.S. Plan) and the Abbott Laboratories Stock Retirement Plan (Puerto Rico). These changes include the transition of recordkeepers, trustees for certain U.S. Plan funds, and custodians for certain P.R. Plan funds. Investors should note that while this impacts plan participants' ability to transact within their retirement accounts, it does not directly affect the company's ongoing business operations or its publicly traded stock in the open market. The blackout period is scheduled to commence on December 24, 2025, and is expected to conclude by the week of January 11, 2026. During this time, participants will be unable to make changes to their contributions, investments, loans, withdrawals, or distributions. The company has formally notified its directors and executive officers of these restrictions as required by Sarbanes-Oxley Act regulations.
ABBOTT LABORATORIES 8-K Report, Material Agreement (Nov 20, 2025)
Abbott Laboratories (ABT) announced a significant strategic move by entering into a definitive agreement to acquire Exact Sciences Corporation for $105.00 per share in cash. This acquisition, structured as a merger where Exact Sciences will become a wholly-owned subsidiary of Abbott, represents a substantial investment by Abbott into the diagnostics and cancer screening market. The transaction is subject to customary closing conditions, including shareholder approval from Exact Sciences and regulatory clearance, such as the Hart-Scott-Rodino Antitrust Improvements Act. This deal is expected to bolster Abbott's presence in precision medicine and oncology. The financial implications include a commitment of up to $20 billion in bridge loans from Morgan Stanley Senior Funding, Inc. to finance the transaction. Abbott has scheduled an investor conference call to discuss the merger, indicating its strategic importance and the company's intent to provide detailed insights into the rationale and expected benefits of this acquisition.
ABBOTT LABORATORIES 8-K Report, Financial Results (Oct 15, 2025)
Abbott Laboratories (ABT) has filed an 8-K report detailing its financial results for the third quarter of 2025, announced on October 15, 2025. The filing includes a press release that presents both GAAP and non-GAAP financial measures. Investors should pay close attention to the company's use of non-GAAP figures, which exclude items such as acquisition-related expenses, restructuring costs, contingent consideration adjustments, certain regulatory costs, and tax-related adjustments. Abbott's management utilizes these non-GAAP measures to offer a clearer view of ongoing operational performance by adjusting for unusual or unpredictable factors. While these measures are intended to provide greater visibility into core business results, it is crucial for investors to consider them alongside the company's GAAP-reported financials. The press release, furnished as an exhibit, will contain the specific details of these financial outcomes and the reconciliation of non-GAAP to GAAP figures.
View all 8-K filings →